These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1546141)

  • 1. Behavioural toxicity of antidepressants with particular reference to moclobemide.
    Hindmarch I; Kerr J
    Psychopharmacology (Berl); 1992; 106 Suppl():S49-55. PubMed ID: 1546141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of moclobemide on psychomotor performance and cognitive function.
    Fairweather DB; Kerr JS; Hindmarch I
    Int Clin Psychopharmacol; 1993; 8(1):43-7. PubMed ID: 8473720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Burkard WP; Bonetti EP; Da Prada M; Martin JR; Polc P; Schaffner R; Scherschlicht R; Hefti F; Müller RK; Wyss PC
    J Pharmacol Exp Ther; 1989 Jan; 248(1):391-9. PubMed ID: 2913284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moclobemide: therapeutic use and clinical studies.
    Bonnet U
    CNS Drug Rev; 2003; 9(1):97-140. PubMed ID: 12595913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of moclobemide on cognition.
    Wesnes KA; Simpson PM; Christmas L; Anand R; McClelland GR
    J Neural Transm Suppl; 1989; 28():91-102. PubMed ID: 2677245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness.
    Fitton A; Faulds D; Goa KL
    Drugs; 1992 Apr; 43(4):561-96. PubMed ID: 1377119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor.
    Dingemanse J; Kneer J; Fotteler B; Groen H; Peeters PA; Jonkman JH
    J Clin Psychopharmacol; 1995 Feb; 15(1):41-8. PubMed ID: 7714227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies.
    Delini-Stula A; Mikkelsen H; Angst J
    J Affect Disord; 1995 Oct; 35(1-2):21-30. PubMed ID: 8557884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressants, alcohol and psychomotor performance.
    Tiller JW
    Acta Psychiatr Scand Suppl; 1990; 360():13-7. PubMed ID: 2248062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moclobemide--placebo-controlled trials.
    Silverstone T
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):133-6. PubMed ID: 8468433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moclobemide: a paradigm of research in clinical psychopharmacology.
    Angst J; Amrein R; Stabl M
    Int Clin Psychopharmacol; 1996 Jun; 11 Suppl 3():3-7. PubMed ID: 8923103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A risk-benefit assessment of moclobemide in the treatment of depressive disorders.
    Norman TR; Burrows GD
    Drug Saf; 1995 Jan; 12(1):46-54. PubMed ID: 7741983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo.
    Versiani M; Nardi AE; Figueira IL; Stabl M
    Acta Psychiatr Scand Suppl; 1990; 360():24-8. PubMed ID: 2123366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double blind trial of moclobemide versus amitriptyline in the treatment of depressive disorders.
    Newburn GM; Fraser AR; Menkes DB; Mullen PE
    Aust N Z J Psychiatry; 1990 Dec; 24(4):475-9. PubMed ID: 2073222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The behavioral toxicity of reversible inhibitors of monoamine oxidase A: laboratory and clinical investigations.
    Fairweather DB; Hindmarch I
    J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):68S-75S. PubMed ID: 7593734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of moclobemide.
    Haefely W; Burkard WP; Cesura A; Colzi A; Kettler R; Lorez HP; Martin JR; Moreau JL; Richards JG; Schaffner R
    Clin Neuropharmacol; 1993; 16 Suppl 2():S8-18. PubMed ID: 8313402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moclobemide (Ro 11-1163) safety in depressed patients.
    Moll E; Hetzel W
    Acta Psychiatr Scand Suppl; 1990; 360():69-70. PubMed ID: 2248078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function.
    Montkowski A; Barden N; Wotjak C; Stec I; Ganster J; Meaney M; Engelmann M; Reul JM; Landgraf R; Holsboer F
    J Neuroendocrinol; 1995 Nov; 7(11):841-5. PubMed ID: 8748120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RIMA--a new concept in the treatment of depression with moclobemide.
    Amrein R; Hetzel W; Stabl M; Schmid-Burgk W
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):123-32. PubMed ID: 8468432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moclobemide versus amitriptyline in the treatment of depression: two small double-blind multicentre studies in Belgium.
    Beckers G; Vereecken A; de Bleeker E; Jaunes C; Sieben G; Faidherbe J; Wolfrum C; Berger M; Hellstern K; Ward J
    Acta Psychiatr Scand Suppl; 1990; 360():52-3. PubMed ID: 2248072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.